The Company is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The Company is involved in the manufacturing and sale of pharmaceuticals and functional health food. The pharmaceuticals include obesity treatment, retinopathy treatment, periodontal disease treatments, otitis media treatments, and psoriasis treatments. The functional health food include visceral fat reducing health functional food named Obi-X. In addition, the Company is engaged in the manufacturing and sale of anti-wrinkle cosmetics and deep-sea beard toothpastes. The Company distributes its products within the domestic market and to overseas markets, including America, Europe and Australia. The Company was founded on June 03, 1999. and its shares are listed on KOREA NEW EXCHANGE(KONEX) on October 25, 2016.
Headquarters
65 Techno 3Ro, Yuseong-Gu
Daejeon; Daejeon;
Contact Details: Purchase the Angiolab Inc. report to view the information.
Website: http://www.angiolab.co.kr
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service